Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in

Ascenta Capital

WebsiteLinkedIncbCrunchbase
Status
ACTIVE
Global HQ
Wilmington, United States
Countries of investment
  • United States
Investment stages
  • Seed
  • Series A
Industries
  • Biotechnology
  • Pharma
  • Life Sciences
About
Ascenta Capital supports biotech innovators developing breakthrough medicines, providing seed and series A capital to accelerate research and clinical development.
Min check size
$100K
Max check size
$20M
Fund size
NPS

Investment Thesis

Ascenta Capital invests in early-stage biotech companies translating scientific discoveries into new therapies.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Founders and partners bring extensive experience in financial services, technology investments, and strategic business development with private equity backgrounds.

Ascenta Capital Contacts Information

Primary contact

Secondary contact

Team

Evan Rachlin – Co-Founder & Managing Partner

Lorence Kim – Co-Founder & Managing Partner

Jeff Chodakewitz – Advisory Partner

Michael Rosenblatt – Advisory Partner

Paul Deutsch – Advisory Partner

John Gutierrez – Vice President

Leighanne Oh – Vice President

Dave Shields – Chief Financial Officer

Tami Daelen – Chief of Staff

Nancy McAdams – Executive Assistant

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp